Overview and Scope
Intratumoral cancer therapies refer to treatments that are directly injected or applied to a tumor. These therapies are specifically designed to target tumor cells and can be used with other cancer treatments, such as chemotherapy and radiation therapy.
Sizing and Forecast
The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $124.82 billion in 2023 to $141.55 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to advancements in cancer research, increasing cancer incidence, demand for precision medicine, clinical evidence and research initiatives, unmet medical needs..
The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $221.46 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to advancements in immunotherapy, increased adoption of precision medicine, clinical trial expansion, rising focus on rare cancers, regulatory support and approvals.. Major trends in the forecast period include exploration of intratumoral immunomodulators, integration of image-guided therapies, application of hyperthermia in intratumoral treatments, clinical trials for combination therapies, regulatory support for intratumoral therapies..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report
The intratumoral cancer therapies market covered in this report is segmented –
1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines
2) By Application: Lung Cancer, Breast Cancer, Malenoma, Prostate Cancer, Head and Neck Cancer, Other Applications
3) By End Users: Hospitals, Cancer Research Centres, Clinics
North America was the largest region in the intratumoral cancer therapies market in 2023. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=9979&type=smp
Major Driver Impacting Market Growth
The increasing incidence of cancer is expected to propel the growth of the intratumoral cancer therapies market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Intratumoral cancer therapies are used in diagnosing and treating cancer that help in avoiding off-target toxicities, dose-limiting toxicities, and adverse effects due to immune stimulation for patients suffering from cancer. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023, reflecting a growth of 3.16% from 1,898,160 in 2021. Therefore, the increasing incidence of cancer is driving the growth of the intratumoral cancer therapies market.
Key Industry Players
In September 2022, CytoReason Ltd, an Israel-based biotechnology company, collaborated with Pfizer Inc. to use artificial intelligence (AI) for drug discovery and development. Through this agreement, Pfizer’s drug research activities will use the company’s AI technologies. The arrangement, which may be valued up to $110 million over the following five years, calls for Pfizer to contribute $20 million in stock, provide options to license CytoReason’s platform and disease models, and give more project assistance. Prifzer Inc. is a US-based pharmaceutical company that serves intestine cancer therapeutics.
The intratumoral cancer therapies market report table of contents includes:
1. Executive Summary
2. Intratumoral Cancer Therapies Characteristics
3. Intratumoral Cancer Therapies Trends And Strategies
4. Intratumoral Cancer Therapies – Macro Economic Scenario
5. Global Intratumoral Cancer Therapies Size and Growth
…..
32. Global Intratumoral Cancer Therapies Competitive Benchmarking
33. Global Intratumoral Cancer Therapies Competitive Dashboard
34. Key Mergers And Acquisitions In The Intratumoral Cancer Therapies
35. Intratumoral Cancer Therapies Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
